Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Koji Kifune is active.

Publication


Featured researches published by Koji Kifune.


Journal of Dermatology | 1997

Systemic 70% Deacetylated Chitin (DAC‐70) as a Treatment for MRL/lpr Murine Lupus; Reduction of Immunoglobulin Deposition in the Skin and Kidneys

Yasuhiro Horiuchi; Ryoichi Tsurutani; Koji Kifune

To the Editor: Current therapy for systemic lupus erythematosus (SLE) includes corticosteroids, various immunosuppressants, and plasma exchange. However, there can be serious adverse reactions to these drugs. The authors have thus sought to develop a new and safe therapy for SLE. Chitin (1) is a polymer of D-glucosamine, beta-poly-Nacetyl D-glucosamine. From deacetylation ratio values, it has been possible to identify various derivatives of chitin, each with its own degree of immunopotentiating capacity; 70% deacetylated chitin (DAC-70) has been shown to be the most effective immuno-adjuvant (2). In this study, we assessed the use of systemic DAC-70 in treating MRL/lpr lupus mice (3). MRL/Mp-Ipr/lprmice (3), 5 week-old virgin females, were purchased from Charles RiverJapan, Inc. and maintained under specific pathogen free (SPF) conditions in the Experimental Animal House (room temperature, 25°C) of the Unitika Research and Development Center, Kyoto. Eight mice Fig. 1. a) DAC-70 treated mice skin samples show a remarkably reduced degree and/or virtually no staining for IgG at the DE]. (x40) b) The DE] of non-treated mice skin shows strong IgG linear deposition. (x40)


Archive | 1993

A New Slow-Releasing Drug Delivery System for Chemically Combined Cisplatin with Chitin for Intraoperative Local Application: An Experimental Study

Kenji Suzuki; Hiroshi Yoshimura; Hiroshi Matsuura; Tsukasa Kotoh; Teruhisa Nakamura; Ryoichi Tsurutani; Koji Kifune

In order to concentrate anticancer agents in residual cancer cells and to decrease side effects by supressing the systemic concentration of drug, we developed a new drug delivery system, Plachitin, for intraoperative local application after esophagectomy. Chitin and cisplatin were coupled by covalent bond, and in this system chitin was used as a carrier for cisplatin. Chitin is metabolized in the human body by enzymes such as lysozyme and is absorbed in 1–3 months. It is this slow breakdown of chitin that allows Plachitin to release cisplatin over a long period of time and deliver high concentrations of drug to local lesions.


Archive | 1985

Shaped chitin body

Kenzo Motosugi; Koji Kifune; Yasuhiko Yamaguchi; Yasuo Nobe; Hiroyuki Tanae


Archive | 1981

Process for the production of chitin fibers

Koji Kifune; Katsuhiro Inoue; Shigeru Mori


Archive | 1985

Porous chitin shaped article and production thereof

Koji Kifune; Hiroyuki Tanae; Yasuhiko Yamaguchi; Kenzo Motosugi


Archive | 1991

Slow-releasing composition of platinum-containing anticancer agent

Ryoichi Tsurutani; Koji Kifune; Yuriko Nakamura


Archive | 1984

Method for manufacture of biodegradable drug donor and drug donor made thereby

Koji Kifune


Archive | 1984

Insulin releasing supplier

Koji Kifune


Archive | 1989

Chitin fibers and process for the production of the same

Koji Kifune; Katsuhiro Inoue; Shigeru Mori


Japanese Journal of Oral & Maxillofacial Surgery | 1998

Influence of deacetylation of chitin on fibroblast-like cells and osteoblasts

Kazuhiro Tominaga; Naohiro Tominaga; Michio Tokuhisa; Koji Kifune; Toshio Umemoto; Jinichi Fukuda; Akio Mizuno

Collaboration


Dive into the Koji Kifune's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge